Effect of Intranasal Anti-IgE Antibodies on IgE Production

• Register: ClinicalTrials.gov
• Last refreshed on: 16 December 2017
• Main ID: NCT03019237
• Date of registration: 10/01/2017
• Prospective Registration: No
• Primary sponsor: Medical University of Vienna
• Public title: Effect of Intranasal Anti-IgE Antibodies on IgE Production
• Scientific title: The Effect of Intranasal Application of Anti-IgE Antibodies on IgE Production in Patients Suffering From Seasonal Allergic Rhinitis - a Pilot Study
• Date of first enrolment: November 2012
• Target sample size: 15
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03019237
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Triple (Participant, Investigator, Outcomes Assessor).
• Phase: N/A

Countries of recruitment

Austria

Contacts

• Name: Verena Niederberger, MD
• Affiliation: Medical University of Vienna

Key inclusion & exclusion criteria

Inclusion Criteria:

birch pollen allergy

Exclusion Criteria:

history of anaphylaxis autoimmune diseases treatment with corticosteroids, antihistamines,
immunosuppressant drugs, beta-blockers significant medical conditions pregnancy or
lactation



Age minimum: 18 Years
Age maximum: 60 Years
Gender: All

Health Condition(s) or Problem(s) studied

Allergy

Intervention(s)

Other: intranasal saline

Drug: anti-IgE

Other: intranasal allergen

Primary Outcome(s)

change of allergen-specific IgE [Time Frame: 8 weeks]

Secondary Outcome(s)

changes in total IgE [Time Frame: 8 weeks]

Secondary ID(s)

2012-004193-25

Source(s) of Monetary Support

Please refer to primary and secondary sponsors